Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
暂无分享,去创建一个
Sebastian Harder | Dirk Jäger | D. Jäger | S. Loibl | W. Wels | G. von Minckwitz | S. Hövelmann | M. Kaufmann | S. Al-Batran | E. Jäger | A. Atmaca | A. Knuth | Gunter von Minckwitz | Sibylle Loibl | Manfred Kaufmann | Alexander Knuth | Elke Jäger | Akin Atmaca | Winfried S Wels | S. Harder | A. Maurer | Salah-Eddin Al-Batran | Sascha Hövelmann | Christian Cimpoiasu | Antje Neumann | Aklil Abera | Alexander B Maurer | A. Neumann | A. Abera | Christian Cimpoiasu
[1] R. Kreitman. Recombinant toxins for the treatment of cancer. , 2003, Current opinion in molecular therapeutics.
[2] A. M. Stanley,et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab , 2003, Nature.
[3] C R King,et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. , 1994, The Journal of biological chemistry.
[4] B. Gerstmayer,et al. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene. , 1997, Journal of immunology.
[5] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Hynes,et al. Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. , 1992, The Journal of biological chemistry.
[7] D. Keefe,et al. Trastuzumab‐associated cardiotoxicity , 2002, Cancer.
[8] Y. Oshika,et al. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.
[9] W. Wels,et al. Antitumor effect of an HER2‐specific antibody–toxin fusion protein on human prostate cancer cells , 2001, The Prostate.
[10] I. Pastan,et al. Recombinant toxins for cancer treatment. , 1991, Science.
[11] B. Groner,et al. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2. , 1996, Current topics in microbiology and immunology.
[12] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[13] Andrea Messori,et al. New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .
[14] John Mendelsohn,et al. The EGF receptor family as targets for cancer therapy , 2000, Oncogene.
[15] I. Pastan,et al. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Lohoff,et al. Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. , 1998, Journal of immunology.
[17] D. Kabat,et al. Mechanism of action of Pseudomonas aeruginosa exotoxin Aiadenosine diphosphate-ribosylation of mammalian elongation factor 2 in vitro and in vivo , 1977, Infection and immunity.
[18] E. Kornilova,et al. EGF receptor and p185erbB‐2‐specific single‐chain antibody toxins differ in their cell‐killing activity on tumor cells expressing both receptor proteins , 1995, International journal of cancer.
[19] R. Bast,et al. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. , 2001, Gynecologic oncology.
[20] B. Groner,et al. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. , 1998, Cancer research.
[21] R. Ward,et al. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.
[22] J. D. White,et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Groner,et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo , 2000, International journal of cancer.
[24] B. Groner,et al. Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2‐specific antibody‐toxin , 1997, International journal of cancer.
[25] I. Pastan,et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] Wolzt,et al. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.
[27] B. Groner,et al. Regression of Cutaneous Tumor Lesions in Patients Intratumorally Injected with a Recombinant Single-chain Antibody-toxin Targeted to ErbB2/HER2 , 2003, Breast Cancer Research and Treatment.
[28] B. Groner,et al. Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins. , 1998, Blood.
[29] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[30] B. Groner,et al. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. , 1992, Cancer research.
[31] I. Pastan,et al. Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies , 2000, International journal of cancer.
[32] B. Groner,et al. A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation. , 1999, Hybridoma.
[33] I. Pastan,et al. Inhibition of TNF-α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2 , 2000, The Journal of Immunology.
[34] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[35] W. Wilson,et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.